Abstract -Common features of amyloid-like proteotoxic aggregates are the ability to bind Congo red (congophilia) and to induce fluorescence of thioflavin-T (ThT). Based on the prior discovery that women with preeclampsia exhibit urine congophilia, we proposed that amyloid-like protein aggregates present in urine also circulate in the bloodstream and this feature is linked to disease severity and clinical phenotype. Serum and urine fluorescence attributable to advanced glycation end products was measured in the same samples with correction for autofluorescence. There were no GA-related changes in ThT fluorescence, although near-term serum ThT fluorescence increased compared with nonpregnant state. Compared with healthy pregnant controls, serum and urine ThT fluorescence was increased in severe features of preeclampsia (P<0.001 for both) but not in mild features of preeclampsia or chronic hypertension. Except for chronic hypertension, advanced glycation end products-related fluorescence of serum or urine did not differ from controls. Urine congophilia had a stronger relationship with preeclampsia severity compared with either urine or serum ThT fluorescence. However, serum ThT fluorescence was independently associated with clinical features of hemolysis, elevated liver enzyme levels, and low platelet levels syndrome (P=0.003). We demonstrate that ThT fluorescence, a marker of amyloid-like aggregates, is increased in serum of women with preeclampsia and likely because of their cytotoxicity associated with hemolysis, elevated liver enzyme levels, and low platelet levels syndrome.
P reeclampsia, a pregnancy-specific hypertensive disorder affecting 6% to 8% of pregnancies, contributes considerably to maternal morbidity and mortality worldwide. 1, 2 Historically, research into the pathophysiology of preeclampsia has focused on the coagulation cascade, inflammatory mediators, and pro-and antiangiogenic factors. 3 Recent biomarker discovery, however, led to a novel view of preeclampsia as a pregnancy-specific protein conformational (misfolding) disorder. 4 A common denominator of conformational disorders is an accumulation of supramolecular aggregates of misfolded proteins (collectively named amyloids). 5 Protein misfolding leads to formation of highly organized and generally intractable aggregates that are cytotoxic. 6 Amyloidogenesis links pathogenically several human diseases, including Alzheimer, Parkinson, and prion disease. 6, 7 Features of protein misfolding have been recently described in atherosclerosis and cancer. 8, 9 Small molecules such as Congo red (CR) and thioflavin-T (ThT) have been essential tools to study pathogenic assemblies in misfolding diseases in both tissues and biological fluids. 10 The exact mechanism through which amyloidogenic proteins bind either CR (congophilia) or ThT is not well understood. 11 Although there is agreement that both chemicals bind through electrostatic and hydrophobic interactions, they are not identical in their affinities toward different conformations of misfolded proteins. Because ThT binds to the channels running parallel to the long axis of fibrils, fluorescence of ThT increases greatly upon interaction with fibrils, but less in the presence of prefibrillar aggregates. [11] [12] [13] [14] [15] Conversely, CR binds in grooves formed by β-sheets of partially folded intermediates as well as of fibrils. Furthermore, because of the ability of CR to form interactions with metastable proteins, congophilia has been proposed as a measure of general protein instability. 16 Amyloid fibrils are distinguished by their characteristic elongated morphology and ability to alter the spectral properties of ThT on interaction. This property makes ThT a particularly effective tool for identifying amyloid fibrils in vivo and in vitro. Traditionally, it is believed ThT fluorescence originates only from the dye bound to amyloid fibrils. In vitro experiments showed that incubation of albumin with glucose or with methylglyoxal induces ThT fluorescence, suggesting that chemical adducts of albumin such as advanced glycation end products (AGEs) may contribute to the variation in ThT fluorescence of human serum. 17 This process could be extremely relevant in preeclampsia because AGEs are elevated in maternal circulation of women with preeclampsia and may contribute to their vascular dysfunction. 18, 19 Amyloid-like proteins including Alzheimer disease β-amyloid have been demonstrated in the urine and placenta of women with preeclampsia. 4 Likewise, urine of women with preeclampsia exhibits congophilia, a characteristic of protein misfolding, and this correlated with disease severity. Although in preeclampsia many proteins and protein fragments other than β-amyloid contribute to urine congophilia, 4 the relationship between urine congophilia and serum and urine induction of ThT fluorescence has not been characterized. We hypothesize that serum and urine ThT fluorescence are increased in preeclampsia subjects in direct relationship with urine congophilia. The aim of this study was to perform a systematic analysis of serum and urine ThT fluorescence in relationship to urine congophilia and clinical features of preeclampsia severity.
Methods
The data that support the findings of this study and any additional methodological details that may help replicate our findings are available from the corresponding author on reasonable request.
Subjects and Sample Collection
We analyzed paired serum and urine samples retrieved from 217 reproductive age women of which 195 were pregnant with singletons and 22 were nonpregnant. Among pregnant women, 138 were admitted for evaluation of preeclampsia and enrolled consecutively in the following groups: preeclampsia with severe features (sPE; n=101; median [interquartile range] gestational age [GA], 32 [29] [30] [31] [32] [33] [34] [35] weeks), preeclampsia with mild features (mPE; n=22; GA, 36 [36] [37] weeks), or chronic hypertension (crHTN; n=15; GA, 38 [37] [38] [39] weeks). Maternal blood and urine specimens from normotensive pregnant women (n=57; GA, 39 [38] [39] weeks) and from the nonpregnant women (n=22) served as controls. All normotensive pregnant controls had uncomplicated gestations and delivered at term (>37 weeks) a healthy baby. Participants were recruited from women evaluated by or admitted to the Labor and Birth, antepartum and outpatient units at Yale New Haven Hospital between January 2004 to February 2009. The Yale University Human Investigation Committee approved the study protocol and written informed consent was obtained from all participants.
GA was established based on last menstrual period and early ultrasound evaluation (<20 weeks of gestation). Because patient recruitment and sample collection were completed before publication of the 2013 Task Force recommendations for the definition of preeclampsia we list below elements of the definition of the hypertensive disorders valid at the time of sample collections, specifically the American College of Obstetricians and Gynecologists. 20 With the exception of proteinuria, the key clinical elements responsible for the used diagnoses remained largely the same. Severe preeclampsia was defined based on GA >20 weeks, blood pressure of 160 mm Hg systolic or higher, or 110 mm Hg diastolic or higher on 2 occasions at least 6 hours apart. 21 Other elements of the clinical diagnosis of sPE included cerebral or visual disturbances, epigastric or right upper-quadrant pain, pulmonary edema or cyanosis, oliguria (urinary output <500 mL/24 hours), impaired liver function, and thrombocytopenia (<100 000 cells/µL). Hemolysis, elevated liver enzyme levels, and low platelet levels (HELLP) syndrome was defined as follows: hemolysis (bilirubin ≥1.2 mg/dL or lactate dehydrogenase >600 IU/L), hepatic dysfunction defined as serum aspartate transaminase or alanine transaminase >2× upper limit of normal for local laboratory (for Yale New Haven Hospital the laboratory upper normal limits were aspartate transaminase >34 IU/L, alanine transaminase >34 IU/L), and thrombocytopenia documented by a platelet nadir <100 000 cells/µL.
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Measurement of ThT Fluorescence
Serum (3 µL) and urine (30 µL) were each loaded in duplicate onto wells of a microtiter plate where they were mixed with 8 µmol/L ThT in 100 mmol/L sodium phosphate buffer, pH 7.4 (final volume 250 µL). Fluorescence readings were acquired in a microplate spectrofluorometer (BMG LABTECH CLARIOstar, Ortenberg, Germany) equipped with 444/485 nm excitation/emission filters. To control for possible batch effects or imperfections in the plates, fluorescence from additional duplicate wells measured in the absence of ThT was subtracted from values obtained with ThT and measured in the same plate. ThT fluorescence was expressed as arbitrary units/mL after dilutional correction. In prior experiments, we determine that sample handling, including freezing and thawing, did not impact on either urine congophilia or ThT fluorescence.
AGEs-Related Fluorescence
Serum and urine AGEs-related fluorescence was measured in the wells without ThT using excitation/emission wavelengths of 370/440 nm as described previously.
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Serum and Urine Creatinine and Protein Concentrations
Serum and urinary creatinine levels were measured using a colorimetric assay (Stanbio Laboratory, Boerne, TX) against standard curves derived from known creatinine concentrations. Total protein levels were measured using a bicinchoninic acid/cupric sulfate reagent assay (Pierce BCA Protein Assay Kit, Thermo Scientific, Waltham, MA). Urine ThT fluorescence was expressed as arbitrary units/mg creatinine (mgc). Fractional excretion of ThT-induced fluorescence was calculated for each condition using the formula: (urine/plasma analyte concentration)÷(urine/plasma creatinine concentration)×100. The fractional excretion of an analyte indicates the proportion of the analyte excreted in the urine compared with that filtered by the glomeruli. Fractional excretion is reported in relation to creatinine clearance because creatinine is neither reabsorbed nor significantly secreted. These calculations can help understand whether increased serum levels of an analyte are because of increased production or decreased excretion.
Congophilia
Urine congophilia was determined as previously described using a nitrocellulose-based array. 4 Congophilia results are expressed as % CR Retention (%CRR), which is a measure of spot redness after removing unbound CR. The results of urine congophilia for 54 women have been reported previously. 4 However, for the purpose of this study urine congophilia was remeasured for all cases from the same aliquot with the one used for ThT analysis. The calculation of %CRR was accomplished using the automated image analysis protocol implemented on a mobile phone device. 24 Samples measuring %CRR ≥15% in protein-normalized urine were classified as nonreassuring CRR as described previously. 4 
Statistical Analysis
As far as we know this is the first study of ThT-induced fluorescence of preeclampsia serum, therefore, we based our sample size calculation on the prior experiments where we found that 40 normotensive pregnant women control and 40 sPE urine samples were sufficient to demonstrate statistical significance in urine congophilia and ThT fluorescence between the 2 groups. 4 Data were tested for normality with the Kolmogorov-Smirnov method and reported as median and interquartile range. Comparisons among groups were performed using Kruskal-Wallis ANOVA on Ranks, 2-way ANOVA, and χ 2 tests. Correlations were performed using Spearman rank-order correlation test. Receiver operating characteristic (ROC) curves were created for urine %CRR, urine, and serum ThT fluorescence for identification of women who had a medically indicated delivery for preeclampsia. Multiple stepwise regression analysis was used to explore concurrent relationships between variables and various clinical characteristics as independent variables. Variables were included into the model based on a P<0.05 and excluded if P>0.1. SigmaPlot v12.5 (RockWare, Golden, CO) and MedCalc v16.8.4 (Broekstraat, Belgium) statistical software were used for data analysis. A P value <0.05 was considered to indicate statistical significance.
Results
The demographic, clinical, and outcome characteristics of the pregnant women in the different groups are presented in the Table. Women with crHTN were older, had a higher body weight, and higher gravidity compared with the other groups. Hypertensive women had blood pressure values significantly elevated compared with controls. Dipstick proteinuria was present and significantly higher in preeclampsia women independent of the severity of the clinical features. Women in the sPE but not mPE group had significantly higher 24 hour-proteinuria compared with crHTN group. More women with sPE had neurological symptoms at admission. Women with sPE and mPE delivered earlier compared with either crHTN or pregnant controls. The incidence of intrauterine growth restriction, eclampsia was higher in sPE. In of the women in the sPE group, 25% (25/101) had one or more features of HELLP syndrome with 5 of these presenting with all 3 features. Compared with nonpregnant controls, serum-induced ThT fluorescence in pregnancies with normal outcome was not impacted significantly until late gestation (≥34 weeks; Figure 1A ). However, there was no significant correlation between GA and serum ThT fluorescence in women with normal pregnancy outcomes (r=0.224; P=0.164). Urine had ≈50-fold less ThT fluorescence than serum; there were no differences in urine ThT fluorescence with either pregnancy or across gestation ( Figure 1B ). Serum fluorescence attributable to AGEs was significantly increased in early pregnancy and decreased thereafter with a significant, but an inverse relationship with GA (r=−0.398; P=0.011; Figure 1C ). In urine, fluorescence attributable to AGEs was increased late gestation (≥34 weeks), compared with the nonpregnant state (P<0.001; Figure 1D ). There was no correlation between ThT 
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When compared with healthy controls and crHTN, sPE women displayed significantly higher serum ThT fluorescence (Figure 2A ). Urine ThT fluorescence of women with sPE was significantly higher compared with mPE, crHTN, and pregnant healthy controls ( Figure 2B ). In serum, the highest levels of AGE-related fluorescence were noted in women with crHTN ( Figure 2C ). Women with sPE, mPE, and healthy pregnant controls had similar serum levels of AGE-related fluorescence. Remarkably, healthy pregnant controls had the highest urine AGE-related fluorescence ( Figure 2D ).
We identified an over 3-fold increase in fractional excretion of ThT-induced fluorescence in sPE as compared with nonpregnant and pregnant controls ( Figure 3A) . When we analyzed the data based on GA at diagnosis, we found out that early-onset sPE was associated with increased fractional excretion of ThTinduced fluorescence as compared with their respective GA control group (P=0.001; Figure 3B ). Fractional excretion for late-onset sPE was not different from their pregnant control group (P=0.545). Overall, we found no statistically significant difference in AGE-related fluorescence between nonpregnant controls, pregnant controls, and women with sPE (P=0.161; Figure 3C ). However, when data were separated based on GA, an increased fractional excretion in AGEs was observed for earlyonset sPE that reached the physiological level expected only later in gestation (≥34 weeks). In contrast, in women with lateonset sPE, the renal output of AGE-related fluorescence failed to occur, which rendered their fractional excretion significantly lower from their GA-matched pregnant controls ( Figure 3D) .
Next, we explored the relationship between serum and urine ThT fluorescence and urine congophilia. Among pregnant women, those with nonreassuring CRR had significantly higher ThT fluorescence in both serum ( Figure 4A ) and urine ( Figure 4B ). There was no significant difference in serum ( Figure 4C ) or urine ( Figure 4D ) AGE-related fluorescence based on congophilia level.
To determine whether ThT fluorescence may have diagnostic utility for preeclampsia, we created ROC curves comparing urine %CRR with serum and urine ThT fluorescence and with AGE-related fluorescence measured in the same samples. Both urine and serum ThT fluorescence showed statistical prediction for preeclampsia based on area under the ROC curve >0.5 (ROC area serum ThT, 0.753; 95% confidence interval [CI], 0.658-0.832 and urine ThT, 0.755; 95% CI, 0.660-0.834). However, as diagnostic test for preeclampsia, urine %CRR was significantly superior compared with both urine and serum ThT fluorescence (ROC area %CRR, 0.992; 95% CI, 0.950-1.000; P<0.001 for both; Figure 4E ) for identification of women who had a medically indicated delivery for preeclampsia. Neither serum nor urine AGE-related fluorescence had diagnostic value for preeclampsia (ROC area serum AGE, 0.543; 95% CI, 0.432-0.651 and urine ThT, 0.506; 95% CI, 0.396-0.616).
To explore concurrent relationships between urine congophilia, serum, or urine ThT fluorescence as dependent variables and preeclampsia severity, we performed a multiple linear regression analysis restricted to women with a diagnosis of preeclampsia. Both systolic and diastolic blood pressures were significantly determined by %CRR (systolic r=0.329, diastolic r=0.388, P<0.001 for both), whereas urine and serum ThT fluorescence were eliminated from the model based on P>0.1. There were no significant relationships between the degree of proteinuria (by dipstick or the 24-hour measurement) and any of the 3 dependent variables. Similarly, there were no differences in congophilia or ThT fluorescence among women who either presented with intrauterine growth restriction or developed neurological manifestations including a headache. However, among hypertensive women, serum (but not urine) ThT fluorescence emerged as significantly linked with several laboratory features of HELLP syndrome independent of congophilia and GA. Among them, serum ThT fluorescence correlated significantly with levels of liver enzymes (aspartate transaminase: r=0.407, alanine transaminase: r=0.448, P<0.001 for both) and platelet count (r=−0.267, P=0.013) but not with lactate dehydrogenase activity (P=0.352).
Discussion
It is well-established that both ThT and CR bind to cross-linked β-sheet amyloid-like structures. Interaction with metastable domains of α-helical proteins such as human serum albumin has also been suggested. 14, 25 In this study, we demonstrated that in pregnancies with normal outcome, serum but not urine ThT fluorescence is minimally but significantly increased at term. Recent studies showed that elevated levels of systemic inflammation and oxidative stress are most apparent in mothers who have term, rather than preterm preeclampsia. 26 It is possible that a progressive and heightened state of physiological inflammation and oxidative stress lead toward term to an increased degree of aberrant protein misfolding, and hence increased ThT fluorescence in the absence of clinical manifestation of preeclampsia. 27, 28 Because most women are induced by 41 weeks, preeclampsia will not become clinically manifest as would probably happen if the same mothers would be allowed to progress beyond 42 to 43 weeks. In the absence of clinical manifestation of preeclampsia, these term mothers would be classified as normal although the underlying molecular processes that are associated with preeclampsia are already ongoing. Previous studies outside pregnancy have suggested a link between serum ThT fluorescence and impaired vascular health. 17 Our observation of increased serum ThT fluorescence in normal term pregnancies may explain why both maternal systolic and diastolic blood pressure are consistently increased in the third trimester above first trimester values in pregnancies with normal outcome. 29 Our study clearly indicated that serum, urine, and fractional excretion levels of ThT-induced fluorescence were all increased in preeclampsia. Furthermore, serum and urine ThT fluorescence were significantly increased in preeclampsia women displaying congophilia. These findings strengthen our previous hypothesis that serum and urine amyloid fibrils are an integral component of the pathogenesis of preeclampsia. 4 The possible link between ThT fluorescence and preeclampsia could be vascular dysfunction, which is known to increase the risk for future cardiovascular events in women with a history of preeclampsia. 30 Certainly, amyloid deposits containing apolipoproteins, β-amyloid, and α1-antitrypsin have been found to be associated with atherosclerosis. 31 It is thought that amyloid deposits in vessels decrease vascular elasticity and hence participate in hypertension. Griffin et al 17 measured serum ThT fluorescence in both healthy subjects and nonpregnant patients at high-risk for cardiovascular disease, demonstrating an inverse relationship between ThT fluorescence and small artery elasticity as measured by pulse-wave analysis. Arterial elasticity is also reduced in both currently and formerly preeclamptic women when measured objectively. 32, 33 Similar findings have been exhibited by placental vasculature in women with preeclampsia. 34 Our previous histological studies demonstrated that in preeclampsia placentas, β-amyloid staining was present and more prominent in both basal plate and villous areas compared with GA-matched placentas of women with idiopathic preterm birth. 4 Collectively, our current and previous findings imply that at least part of the increased stiffness of preeclampsia placentas is because of amyloid deposition.
Because preeclampsia often results in renal dysfunction, it is important to demonstrate that the increased serum ThT fluorescence (representing misfolded proteins) of women with preeclampsia is not a manifestation of kidney injury. The increased fractional excretion of ThT-induced fluorescence indicates that the elevated serum ThT fluorescence level in women with sPE is secondary to increased production rather than decreased excretion.
ThT fluorescence was related to clinical severity and the time of preeclampsia onset. In our study, mPE and crHTN groups did not display increased urine or serum ThT fluorescence. In addition, serum ThT fluorescence was an independent factor related to HELLP syndrome, arguable one of the most severe clinical manifestations of preeclampsia. It remains intriguing that in women with sPE, fractional excretion of ThT-induced fluorescence was significantly increased preterm but not at term. Clinical and molecular data exist to support the premise that activation of various molecular pathways could be responsible for the severity and time when the disease becomes clinically manifest. For example, asymptomatic cardiac diastolic dysfunction is evident at midgestation in women who subsequently develop preterm preeclampsia but not in those who develop term preeclampsia. 35 Higher level of placental miR-518a-5p, miR-423, miR-124, and miR-431 were identified in early-onset preeclampsia (<34 weeks GA) cases implying that chemokine receptor CCR6 expression, cell growth, and alternative premRNA splicing in non-neuronal cells pathways could be downregulated when preeclampsia develops early in gestation. 36 Yanagisawa et al 23 established that measurement of AGEspecific fluorescence (ie, AGE-peptide) might serve as a simple and useful test to assess circulating AGE levels and monitor AGE excretion. In our study, serum, urine, and fractional excretion levels of AGE-related fluorescence did not correlate with ThT fluorescence or with clinical measures of preeclampsia severity. This suggests AGEs alone had minimal impact on ThT fluorescence.
The observation that serum AGE-related fluorescence is increased in early gestation in pregnancies with normal outcomes is novel. One possible explanation could be the role of AGEs in limiting excessive trophoblast invasion and placentation in early pregnancy. 37 Increased serum AGE-related fluorescence in pregnant women with crHTN could be explained through tendency for AGEs to accumulate in tissues with aging and cross-linking of collagen. 38 Data from the nonpregnant population suggest elevation of the AGE prototype carboxymethyl-lysine in serum was associated with increased arterial stiffness and hypertension. 39, 40 It has been suggested that detection of amyloid-like adducts in serum using ThT fluorescence could be an important test to predict cardiovascular disease risk. 17 Although serum and urine ThT fluorescence did correlate with preeclampsia and its severity, the data generated from the current study has shown that assessment of urine congophilia performs better at predicting preeclampsia than either urine or serum ThT fluorescence. Nevertheless, the finding that among hypertensive women serum (but not urine) ThT fluorescence was significantly related to lower platelet count and elevated liver enzymes, independent of urine congophilia, could have clinical application. It is plausible that particular types of proteotoxic aggregates with an affinity for ThT are less effectively cleared by the kidney and thus accumulate in maternal circulation. It is also possible that ThT fluorescence may, in fact, correlate with clinical features of preeclampsia such as liver inflammation, that is not assessed part of routine clinical care and will need to be more thoroughly investigated.
Perspectives
The increase in ThT fluorescence in the blood of women with preeclampsia concurs with the notion that pathophysiology of preeclampsia may include protein misfolding and aggregation. The increase in serum ThT-induced fluorescence in women with preeclampsia seems to be the result of increased production of amyloid-like substances rather than decreased excretion. However, the origin of the amyloid-like aggregates responsible for ThTinduced fluorescence remains unknown. The relationship between ThT-induced fluorescence, low platelet count, and elevated liver function tests suggests that the circulating proteotoxic aggregate may induce cellular toxicity and liver inflammation. From a clinical perspective, urine congophilia remains superior at diagnosing preeclampsia compared with serum ThT fluorescence.
